EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitStudienprotokoll

This Is What Metabolic Dysfunction–Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol

Anja M Fischer, Nazim Lechea, Harvey O Coxson

Seminars in Liver Disease · 01.05.2024 · 44 (02) · 226-238

DOI: 10.1055/a-2334-8525 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, erschienen am 01.05.2024. Verfasst von Anja M Fischer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. Hauptthemen laut MEDLINE: Multiparametric Magnetic Resonance Imaging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 109 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction–associated steatotic liver disease (MASLD) is a prevalent condition with a broad spectrum defined by liver biopsy. This gold standard method evaluates three features: steatosis, activity (ballooning and lobular inflammation), and fibrosis, attributing them to certain grades or stages using a semiquantitative scoring system. However, liver biopsy is subject to numerous restrictions, creating an unmet need for a reliable and reproducible method for MASLD assessment, grading, and staging. Noninvasive imaging modalities, such as magnetic resonance imaging (MRI), offer the potential to assess quantitative liver parameters. This review aims to provide an overview of the available MRI techniques for the three criteria evaluated individually by liver histology. Here, we discuss the possibility of combining multiple MRI parameters to replace liver biopsy with a holistic, multiparametric MRI protocol. In conclusion, the development and implementation of such an approach could significantly improve the diagnosis and management of MASLD, reducing the need for invasive procedures and paving the way for more personalized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiparametric Magnetic Resonance ImagingHumansLiverFatty LiverSeverity of Illness IndexBiopsyMagnetic Resonance ImagingLiver Cirrhosis

Autor:innen und Institutionen

  • Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Zitieren

APA

Fischer, A. M., Lechea, N., & Coxson, H. O. (2024). This Is What Metabolic Dysfunction–Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol. Seminars in Liver Disease, 44(02), 226-238. https://doi.org/10.1055/a-2334-8525

Vancouver

Fischer AM, Lechea N, Coxson HO. This Is What Metabolic Dysfunction–Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol. Seminars in Liver Disease. 2024;44(02):226-238. doi:10.1055/a-2334-8525

BibTeX
@article{Fischer2024,
  author = {Fischer, Anja M and Lechea, Nazim and Coxson, Harvey O},
  title = {This Is What Metabolic Dysfunction–Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol},
  journal = {Seminars in Liver Disease},
  year = {2024},
  volume = {44},
  number = {02},
  pages = {226--238},
  doi = {10.1055/a-2334-8525}
}
Kostenlos starten →